FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2518213089> ?p ?o ?g. }

• W2518213089 abstract "Objectives: Over the last four years, INSIGHTS, a quality improvement project, has examined the clinical, laboratory, and electrophysiologic criteria of neuromuscular patients prescribed IVIG across the USBackground: IVIG is used commonly off label for treatment of exacerbations and for maintenance therapy of myasthenia gravis. Due to a lack of positive controlled trials, there is tremendous variability in the types of patients that are prescribed IVIG for myasthenia gravis in clinical practice.Methods: We collected clinical, laboratory, and electrophysiologic data on 585 neuromuscular patients that were prescribed IVIG from across the country. A panel of independent expert neuromuscular neurologists reviewed the information. Positive outcomes were independently determined based on Quality of Life measures, Patient Global Impression of Change, and clinical documentation. Data was entered electronically in the Redcap system at the University of Kansas.Results: We present the data from 89 MG patients who received IVIG. 44 of these patients were naive to IVIG and 68[percnt] of these patients had a positive response. 45 patients had received IVIG previously and 73[percnt] of these patients had a positive outcome. The average dose of IVIG was 1.73 gm/kg/month with a range of 0.4 gm/kg/month to 4gm/kg/month). 59 patients (66[percnt]) were receiving ongoing maintenance therapy while 30 patients (34[percnt]) received treatment only for an exacerbation. Positive response was most strongly associated with the independent reviewers’ determination that the patient was appropriate for IVIG (92[percnt] vs 50[percnt], p=.06) based on progressive generalized weakness. Patient’s age, sex, distribution of weakness, disease time course, and antibody status had no significant association with response.Conclusions: Overall response rates of patients with MG to IVIG was 70[percnt]. This suggests that larger controlled trials of IVIG in MG should be performed with the potential to receive an indication for therapy both for exacerbations and maintenance. Disclosure: Dr Levine has received compensation from Lilly, Pfizer, Griffols, Baxter, Nufactor, Mallinckrodt, and Corinthian Reference Labs. Dr. Vaughn has received personal compensation for activities with Nufactor. Dr. Badger has received personal compensation for activities with Nufactor. Dr. Wolfe has received personal compensation for activities with Grifols and Baxter as a speakers bureau participant and/or advisory board participant. Dr. Grifols has received personal compensation for activities with Grifols and NuFactor as a member of the speakers bureau and as a consultant. Dr. Saperstein has received personal compensation for activities with Grifols, Baxter, NuFactor, and Corintian as a speaker, consultant, and partial owner. Dr. Mozaffar received personal compensation from Genzyme Corporation and Grifols for speaking engagements and has served as an advisory board member for Amicus, Biogen idec, Biomarin, Genzyme, Idera Pharmaceuticals and Ultragenyx. Dr. Mozaffar has receive Dr. Barohn has received personal compensation for activities with Grifols & Genzyme, Speakers Bureau, NuFactor as speaker and consultant. Dr. Katz has received personal compensation for activities with Blue Cross and Griffols. Dr. Dimachkie has received personal compensation for activities with Pfizer, Depomed, Merck, CSL-Behring, Nufactor, Biomarin, Baxter and Catalyst as a consultant, speaker, and advisory board member. Dr. Greer has received personal compensation for activities with NuFACTOR Specialty Pharmacy as an employee. Elissa Ritt has received personal compensation for activities with NuFACTOR Specialty Pharmacy as an employee." @default.
• W2518213089 created "2016-09-16" @default.
• W2518213089 creator A5001954609 @default.
• W2518213089 creator A5004576878 @default.
• W2518213089 creator A5015876206 @default.
• W2518213089 creator A5025085620 @default.
• W2518213089 creator A5046451291 @default.
• W2518213089 creator A5051045476 @default.
• W2518213089 creator A5053296035 @default.
• W2518213089 creator A5070765489 @default.
• W2518213089 creator A5076353519 @default.
• W2518213089 creator A5084044892 @default.
• W2518213089 creator A5089683798 @default.
• W2518213089 creator A5090235979 @default.
• W2518213089 date "2016-04-05" @default.
• W2518213089 modified "2023-09-23" @default.
• W2518213089 title "INSIGHTS: Analysis of IVIG Responsiveness in Patients with Myasthenia Gravis (P3.171)" @default.
• W2518213089 hasPublicationYear "2016" @default.
• W2518213089 type Work @default.
• W2518213089 sameAs 2518213089 @default.
• W2518213089 citedByCount "0" @default.
• W2518213089 crossrefType "journal-article" @default.
• W2518213089 hasAuthorship W2518213089A5001954609 @default.
• W2518213089 hasAuthorship W2518213089A5004576878 @default.
• W2518213089 hasAuthorship W2518213089A5015876206 @default.
• W2518213089 hasAuthorship W2518213089A5025085620 @default.
• W2518213089 hasAuthorship W2518213089A5046451291 @default.
• W2518213089 hasAuthorship W2518213089A5051045476 @default.
• W2518213089 hasAuthorship W2518213089A5053296035 @default.
• W2518213089 hasAuthorship W2518213089A5070765489 @default.
• W2518213089 hasAuthorship W2518213089A5076353519 @default.
• W2518213089 hasAuthorship W2518213089A5084044892 @default.
• W2518213089 hasAuthorship W2518213089A5089683798 @default.
• W2518213089 hasAuthorship W2518213089A5090235979 @default.
• W2518213089 hasConcept C126322002 @default.
• W2518213089 hasConcept C141071460 @default.
• W2518213089 hasConcept C159110408 @default.
• W2518213089 hasConcept C1862650 @default.
• W2518213089 hasConcept C187212893 @default.
• W2518213089 hasConcept C2777014857 @default.
• W2518213089 hasConcept C2778105408 @default.
• W2518213089 hasConcept C2779951463 @default.
• W2518213089 hasConcept C2779974597 @default.
• W2518213089 hasConcept C2780247198 @default.
• W2518213089 hasConcept C2908964109 @default.
• W2518213089 hasConcept C2910384678 @default.
• W2518213089 hasConcept C512399662 @default.
• W2518213089 hasConcept C535046627 @default.
• W2518213089 hasConcept C71924100 @default.
• W2518213089 hasConceptScore W2518213089C126322002 @default.
• W2518213089 hasConceptScore W2518213089C141071460 @default.
• W2518213089 hasConceptScore W2518213089C159110408 @default.
• W2518213089 hasConceptScore W2518213089C1862650 @default.
• W2518213089 hasConceptScore W2518213089C187212893 @default.
• W2518213089 hasConceptScore W2518213089C2777014857 @default.
• W2518213089 hasConceptScore W2518213089C2778105408 @default.
• W2518213089 hasConceptScore W2518213089C2779951463 @default.
• W2518213089 hasConceptScore W2518213089C2779974597 @default.
• W2518213089 hasConceptScore W2518213089C2780247198 @default.
• W2518213089 hasConceptScore W2518213089C2908964109 @default.
• W2518213089 hasConceptScore W2518213089C2910384678 @default.
• W2518213089 hasConceptScore W2518213089C512399662 @default.
• W2518213089 hasConceptScore W2518213089C535046627 @default.
• W2518213089 hasConceptScore W2518213089C71924100 @default.
• W2518213089 hasOpenAccess W2518213089 @default.
• W2518213089 hasRelatedWork W1504654674 @default.
• W2518213089 hasRelatedWork W2337307418 @default.
• W2518213089 hasRelatedWork W2473107896 @default.
• W2518213089 hasRelatedWork W2587495866 @default.
• W2518213089 hasRelatedWork W2781904792 @default.
• W2518213089 hasRelatedWork W2790507197 @default.
• W2518213089 hasRelatedWork W2800288795 @default.
• W2518213089 hasRelatedWork W2800528626 @default.
• W2518213089 hasRelatedWork W2801706337 @default.
• W2518213089 hasRelatedWork W2802731780 @default.
• W2518213089 hasRelatedWork W2803651213 @default.
• W2518213089 hasRelatedWork W2806319173 @default.
• W2518213089 hasRelatedWork W2811297374 @default.
• W2518213089 hasRelatedWork W2885049414 @default.
• W2518213089 hasRelatedWork W2973602172 @default.
• W2518213089 hasRelatedWork W3043068731 @default.
• W2518213089 hasRelatedWork W3161104252 @default.
• W2518213089 hasRelatedWork W3198538026 @default.
• W2518213089 hasRelatedWork W863015286 @default.
• W2518213089 hasRelatedWork W1780089774 @default.
• W2518213089 hasVolume "86" @default.
• W2518213089 isParatext "false" @default.
• W2518213089 isRetracted "false" @default.
• W2518213089 magId "2518213089" @default.
• W2518213089 workType "article" @default.